Introduction {#s1}
============

Biologically active molecules rely on the interaction with one or more molecular targets (Hughes et al., [@B18]). In the context of hit discovery both in pharmaceutical or in phytopharmaceutical industries, a major objective is to be able to screen molecule candidates for their activity toward a target of interest, and assessing compound activity toward off-targets, that can cause adverse effects *in vivo* (Rouquié et al., [@B33]). Testing activity of every candidate on a battery of targets represent a complex task that requires major R&D costs. A potential solution to predict candidate\'s activity with a lower cost is to perform computational methods using more general measured or calculated descriptors (Chen et al., [@B8]; Vamathevan et al., [@B37]).

A commonly used technique is to compute descriptors from chemical structures, like the extended-connectivity fingerprints (ECFPs) and use them for prediction, relying on the quantitative structure-activity relationship (QSAR) principle, i.e., molecules sharing a similar structure may share a similar activity profile (Rogers and Hahn, [@B32]; Cherkasov et al., [@B9]). However, such molecule descriptors show limitations: they do not perform well for all target prediction tasks depending on the quantity and quality of available activity data, prediction is limited to the applicability domain (depending on the training set used), and a small change in chemical structure can lead to a large change in biological response (activity cliffs) (Cruz-Monteagudo et al., [@B11]).

Additional descriptors have been proposed to circumvent such QSAR drawbacks, such as measurements from large scale biological assays (Petrone et al., [@B31]; Laufkötter et al., [@B22]). Results from high throughput screening (HTS) assays, such as bioactivity experiments, can be used as fingerprints (HTSFPs) in predictive models for specific targets. Petrone et al. ([@B31]) showed that models using HTSFPs were outperforming models using ECFPs for certain targets, and that HTSFP models\' predictions were covering a large structural diversity. The main limiting factor of such models is the sparsity of available activity data. Besides bioactivity data, more integrative large-scale biological measurements, like transcriptomics or cell morphology readouts can be used for target prediction (Aliper et al., [@B2]; Pabon et al., [@B28]; Scheeder et al., [@B34]; Simm et al., [@B35]; Hofmarcher et al., [@B16]; Kuthuru et al., [@B19]; Lapins and Spjuth, [@B21]).

Compound-induced gene expression data are gathered from biological experiments reflecting how the compound acted on one or multiple targets in a specific biological context. Cancer cell lines, being easily cultured, are a commonly used model to generate gene expression data. Hughes et al. ([@B18]) proved that enough data allows to use pattern-matching algorithms to study similarity between signatures coming from drug induction (Hughes et al., [@B18]). Lamb et al. ([@B20]) invented the concept of Connectivity Map (CMAP), creating relationships between small molecules, genes and diseases (Lamb et al., [@B20]). Since then, transcriptomics data have been shown to be useful to identify new molecules with biological activity (Hieronymus et al., [@B15]; Wei et al., [@B40]). Recently, a large public CMAP L1000 dataset was released representing more than 300,000 Gene Expression Signatures (GESs) of cell line responses to so-called perturbagens (Subramanian et al., [@B36]). GESs were produced for more than 20,000 compounds in 80 human cancer cell lines, tested at various concentration and exposition time. The large scale of this dataset allows the use of GESs in machine learning models for target prediction or drug repurposing (Lee et al., [@B23]; De Wolf et al., [@B12]).

In the current work, we investigated whether we could predict compound activity toward a larger number of molecular targets based on their GESs extracted from the CMAP L1000 dataset. In addition, we were interested to reveal how machine learning models using GESs perform compared to models using more traditional QSAR descriptors, such as the Morgan fingerprints.

We show that random forest models built using compound-induced GES were able to effectively predict targets, especially if they were produced from a cell line showing similar GESs between active compounds on the evaluated target. For 25% of the target prediction tasks, GESs models had similar or higher performances than models using Morgan fingerprints, offering an opportunity to escape from the chemical space limitation associated with QSAR approaches.

Materials and Methods {#s2}
=====================

Gene Expression Signatures (GESs) Acquisition
---------------------------------------------

The CMAP L1000 dataset was obtained from two GEO repositories: GSE92742, corresponding to the first phase of L1000 (pilot, 2012--2015) and GSE70138, which is the second phase (production, on-going). GESs generation was described by Subramanian et al. ([@B36]).

For this study, we only used Level 5 GESs meaning that each GES is represented by an instance, that is a combination of a perturbagen (chemical or gene deletion), cell line, concentration and time point, and is composed by the plate-normalized expression z-scores of the whole genome, inferred from 978 landmark genes (measured gene that can be used for whole transcriptome inference). We focused on landmark signatures of compound perturbagens, which comprises 333,273 GESs for 21,300 unique compounds. GESs obtained in the exact same condition were averaged, to have one signature per condition.

Among all obtained GESs, the ones generated at a 10 μM and 24 h time point were selected (as shown in [Figure 1](#F1){ref-type="fig"}), as this condition was the most represented in the dataset and facilitate the comparison of results. GESs from the 8 most profiled cell lines were used; cell line and number of GESs are presented in [Table 1](#T1){ref-type="table"}. Also, only GESs generated by compounds with known structure were selected. In total, the working dataset contains 39,544 GESs obtained from 9,035 compounds.

![Data analysis pipeline performed in current work. Starting from the CMAP L1000 dataset, signatures produced at 10 μM and 24 h from 8 cell lines were extracted and used in t-SNE and distance plots. One dataset was built per cell line (GES and corresponding compound structure), and each of these datasets were restricted to compounds having known annotations (active or inactive) for the evaluated target. For each target---cell line dataset, a first model was built using the gene expression signatures (GES model). Alongside, a second counterpart model was built using the Morgan fingerprints of compounds whose signatures were used in the first model (Morgan FP model).](fchem-08-00296-g0001){#F1}

###### 

The 8 core cell lines used in this work, with their corresponding number of GESs for compounds with known structure tested at 10 μM/24 h.

  **Cell line**   **Primary site**   **Subtype**                              **Number of 10 μM−24 h signatures**
  --------------- ------------------ ---------------------------------------- -------------------------------------
  A375            Skin               Malignant melanoma                       3,525
  A549            Lung               Non small cell lung cancer\| carcinoma   5,267
  HA1E            Kidney             Normal kidney                            3,646
  HCC515          Lung               Carcinoma                                1,932
  HT29            Large intestine    Colorectal adenocarcinoma                3,192
  MCF7            Breast             Adenocarcinoma                           7,546
  PC3             Prostate           Adenocarcinoma                           8,071
  VCAP            Prostate           Carcinoma                                6,365

Activity Data Acquisition
-------------------------

Annotations about activity or inactivity was retrieved from the PubChem BioAssay database, using available CIDs documented in the L1000 signature metadata, excepted for TUBB actives, that were extracted from the Drug Repurposing Hub of the LINCS (Wang et al., [@B39]; Corsello et al., [@B10]). Activity data were compiled in a binary activity matrix (1 for active, 0 for inactive, empty if unknown). At least one annotation among 1,388 targets was found for 7,804 of the 9,035 compounds (512,406 annotations were found, representing 4.8% of the full activity matrix).

Representation of Chemical and Biological Spaces
------------------------------------------------

For each compound, binary Morgan fingerprints were computed. The Morgan fingerprints were employed as input of a t-SNE (t-distributed stochastic neighbor embedding) algorithm (using the sklearn implementation) using Dice distance as metric, to reduce the data to a two-dimensional output that can be plotted to represent the chemical space (Van Der Maaten and Hinton, [@B38]; Pedregosa et al., [@B29]). Information of the number of targets per compound was included as color-code using a blue gradient in the plot.

The whole extracted 10 μM/24 h signature dataset was used as input for a second t-SNE using the cosine distance metric, representing the overall biological (response) space wherein each cell line was color-coded in the plot. For every cell line, a t-SNE using the cosine distance metric was performed using all GESs profiled in the cell line, generating 2D biological space.

Machine Learning Modeling
-------------------------

Targets for which we know at least 50 active compounds (representing between 1 and 63% of active per target) were selected for machine learning modeling in order to have a minimum number of actives in test sets to evaluate the model performances, and for computational time purposes. Complete information on the number of active and inactive compounds for these selected targets is listed in [Table 2](#T2){ref-type="table"}.

###### 

Molecular targets used in this work, with number of active and inactive compounds in total, and in each cell line GES dataset.

  **Gene name**   **Total inactive**   **Total active**   **Description**                                                         **A375**   **A549**   **HA1E**   **HCC515**   **HT29**   **MCF7**   **PC3**   **VCAP**                                                     
  --------------- -------------------- ------------------ ----------------------------------------------------------------------- ---------- ---------- ---------- ------------ ---------- ---------- --------- ---------- ------- ----- ------- ----- ------- ----- ------- -----
  ABCB1           801                  96                 ATP binding cassette subfamily B member 1 \[HGNC:40\]                   331        42         545        60           424        50         211       32         317     32    770     95    772     95    608     68
  ABHD5           2,458                57                 Abhydrolase domain containing 5 \[HGNC:21396\]                          908        22         1,533      47           \-         \-         \-        \-         \-      \-    2,030   57    2,045   57    1,730   52
  ALOX15          1,136                101                Arachidonate 15-lipoxygenase \[HGNC:433\]                               508        27         764        92           808        52         496       33         498     27    1,062   97    1,066   96    804     91
  AR              1,085                103                Androgen receptor \[HGNC:644\]                                          580        36         639        64           757        62         374       36         572     37    1,038   94    1,036   93    682     69
  ATAD5           2,213                97                 Atpase family, AAA domain containing 5 \[HGNC:25,752\]                  1,007      43         1,466      70           1288       60         638       41         922     42    2,087   90    2,090   88    1,629   72
  ATXN2           1,897                143                Ataxin 2 \[HGNC:10555\]                                                 695        36         1,139      104          950        50         501       41         652     41    1556    123   1,558   129   1,243   102
  BAZ2B           1,252                143                Bromodomain adjacent to zinc finger domain 2B \[HGNC:963\]              516        63         873        101          653        76         319       37         470     56    1,199   135   1,197   136   974     112
  BRCA1           3,008                160                BRCA1, dna repair associated \[HGNC:1100\]                              1,117      67         1945       116          1,519      63         800       33         1,014   50    2,537   148   2,549   150   2,134   131
  CBX1            1,999                80                 Chromobox 1 \[HGNC:1551\]                                               899        41         1,412      64           1,120      61         532       38         809     40    1,899   75    1,904   76    1,576   67
  CHRM1           2,433                86                 Cholinergic receptor muscarinic 1 \[HGNC:1950\]                         906        49         1,544      62           1,055      59         460       39         791     48    2,036   84    2051    83    1,739   65
  CHRM4           2,476                70                 Cholinergic receptor muscarinic 4 \[HGNC:1953\]                         908        45         1,552      54           1,057      55         460       40         793     45    2,049   68    2,064   67    1,751   54
  CHRM5           2,478                62                 Cholinergic receptor muscarinic 5 \[HGNC:1954\]                         908        41         1,553      47           1,057      49         461       36         793     39    2,050   62    2,065   61    1,751   50
  CYP1A2          307                  526                Cytochrome P450 family 1 subfamily A member 2 \[HGNC:2596\]             145        265        183        399          219        428        136       277        144     261   299     505   294     505   183     410
  CYP2C19         717                  276                Cytochrome P450 family 2 subfamily C member 19 \[HGNC:2621\]            329        151        514        213          486        228        289       138        324     148   688     271   684     272   524     225
  CYP2C9          708                  270                Cytochrome P450 family 2 subfamily C member 9 \[HGNC:2623\]             310        157        510        197          476        222        285       126        305     154   679     264   674     263   517     207
  CYP3A4          1,153                164                Cytochrome P450 family 3 subfamily A member 4 \[HGNC:2637\]             472        113        780        104          847        133        561       64         467     110   1,070   160   1069    161   802     118
  DRD1            1,843                99                 Dopamine receptor D1 \[HGNC:3020\]                                      807        54         1,295      71           1028       78         526       55         725     54    1,762   91    1,762   91    1,450   71
  DRD2            2,262                95                 Dopamine receptor D2 \[HGNC:3023\]                                      769        58         1,371      73           956        84         474       55         683     57    1,858   93    1873    93    1,541   74
  DRD3            2,446                142                Dopamine receptor D3 \[HGNC:3024\]                                      877        76         1,432      110          1,129      114        551       78         823     75    2,004   139   2,017   139   1,569   111
  EPAS1           2,443                70                 Endothelial PAS domain protein 1 \[HGNC:3374\]                          --         --         1,524      52           --         --         --        --         --      --    2,021   64    2,033   67    1,723   57
  FEN1            2,100                53                 Flap structure-specific endonuclease 1 \[HGNC:3650\]                    961        23         1,496      29           1,213      28         --        --         866     21    1,990   46    1,999   46    1,669   32
  GFER            1,589                89                 Growth factor, augmenter of liver regeneration \[HGNC:4236\]            679        37         1,153      59           813        46         363       21         600     29    1,519   81    1,519   81    1,294   70
  GLS             2,989                66                 Glutaminase \[HGNC:4331\]                                               1,240      22         1,878      46           1,515      31         --        --         --      --    2,560   58    2,574   59    2,072   53
  GMNN            2,079                161                Geminin, DNA replication inhibitor \[HGNC:17493\]                       969        67         1,392      121          1,224      72         569       43         884     63    1,972   146   1,974   153   1,552   128
  HPGD            1,464                92                 15-Hydroxyprostaglandin dehydrogenase \[HGNC:5154\]                     575        38         1,000      74           962        62         618       39         567     37    1363    89    1,363   86    1,060   71
  HSD17B10        1,211                107                Hydroxysteroid 17-beta dehydrogenase 10 \[HGNC:4800\]                   516        48         827        84           858        81         548       47         506     48    1,134   99    1,135   95    866     81
  HSP90AA1        666                  56                 Heat shock protein 90 alpha family class A member 1 \[HGNC:5253\]       295        25         453        39           419        38         --        --         288     25    640     50    637     50    502     40
  HSPB1           876                  76                 Heat shock protein family B (small) member 1 \[HGNC:5246\]              461        40         522        45           600        53         304       26         454     41    837     72    837     71    558     47
  HTR1A           412                  60                 5-Hydroxytryptamine receptor 1A \[HGNC:5286\]                           186        34         279        49           232        55         122       37         180     34    401     58    400     58    315     50
  IL1B            1,773                206                Interleukin 1 beta \[HGNC:5992\]                                        589        54         1,005      165          768        78         382       54         541     54    1,385   190   1,391   196   1,122   163
  JAK2            895                  80                 Janus kinase 2 \[HGNC:6192\]                                            378        39         663        58           478        43         248       29         364     40    867     71    867     74    723     55
  JUN             842                  97                 Jun proto-oncogene, AP-1 transcription factor subunit \[HGNC:6204\]     442        49         491        67           570        72         279       41         435     49    801     91    799     91    523     70
  KCNH2           363                  190                Potassium voltage-gated channel subfamily H member 2 \[HGNC:6251\]      174        119        212        136          250        161        128       104        173     119   331     183   329     184   228     139
  KDM4A           1,607                192                Lysine demethylase 4A \[HGNC:22978\]                                    693        76         1,130      125          834        87         379       42         603     69    1,529   173   1,536   175   1,286   140
  KDM4E           1,389                124                Lysine demethylase 4E \[HGNC:37098\]                                    543        43         999        88           880        70         547       40         530     42    1,320   109   1,321   110   1,057   95
  MITF            3,626                132                Melanogenesis associated transcription factor \[HGNC:7105\]             1,170      42         2,238      91           1,562      51         858       42         1,083   37    2,832   116   2,871   120   2,460   93
  MLLT3           14,566               101                MLLT3, super elongation complex subunit \[HGNC:7136\]                   --         --         2,244      26           --         --         --        --         --      --    3,002   33    3,461   50    3,095   46
  MPHOSPH8        506                  52                 M-Phase phosphoprotein 8 \[HGNC:29810\]                                 278        21         365        39           403        41         253       29         278     21    490     48    485     50    382     43
  MYC             2,069                121                MYC proto-oncogene, bHLH transcription factor \[HGNC:7553\]             --         --         1,067      113          --         --         --        --         --      --    1,230   114   1,249   117   1,151   115
  NFE2L2          2,850                226                Nuclear factor, erythroid 2 like 2 \[HGNC:7782\]                        1,142      94         1,816      148          1,355      153        620       83         1,013   95    2,425   204   2,439   204   2,023   152
  NFKB1           2,875                107                Nuclear factor kappa B subunit 1 \[HGNC:7794\]                          730        23         1,608      91           1,237      37         814       29         716     22    1,978   100   2,000   101   1,742   94
  NOD1            1,056                51                 Nucleotide binding oligomerization domain containing 1 \[HGNC:16390\]   --         --         754        43           --         --         --        --         409     21    1,010   47    1,010   49    844     40
  NOD2            2,578                59                 Nucleotide binding oligomerization domain containing 2 \[HGNC:5331\]    952        23         1,629      53           1,124      21         --        --         836     23    2,152   57    2,165   59    1,837   48
  NPSR1           1,007                55                 Neuropeptide S receptor 1 \[HGNC:23631\]                                --         --         712        44           554        21         --        --         --      --    959     52    956     54    777     50
  NR3C1           925                  54                 Nuclear receptor subfamily 3 group C member 1 \[HGNC:7978\]             --         --         636        38           692        34         451       25         --      --    896     54    890     54    659     47
  NR5A1           419                  69                 Nuclear receptor subfamily 5 group A member 1 \[HGNC:7983\]             190        22         285        50           239        29         --        --         --      --    408     60    407     64    322     50
  OPRK1           1,122                51                 Opioid receptor kappa 1 \[HGNC:8154\]                                   455        29         805        41           564        34         --        --         428     29    1,068   51    1,070   50    895     41
  PIP4K2A         1,898                88                 Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha \[HGNC:8997\]    609        31         1,082      66           812        34         --        --         566     23    1,486   84    1,501   83    1,206   72
  PLA2G7          1,907                57                 Phospholipase A2 group VII \[HGNC:9040\]                                828        27         1,367      37           995        37         --        --         737     28    1,825   52    1,826   51    1,534   37
  PLK1            1,935                108                Polo like kinase 1 \[HGNC:9077\]                                        631        45         1,125      82           836        39         431       23         590     36    1,531   100   1,542   102   1,241   88
  POLB            1,166                53                 DNA polymerase beta \[HGNC:9174\]                                       480        22         850        37           646        30         --        --         462     21    1,113   50    1,113   50    932     39
  POLH            2,202                70                 DNA polymerase eta \[HGNC:9181\]                                        858        26         1,342      44           1,015      37         --        --         749     23    1,827   61    1,838   64    1,532   48
  POLI            1,726                79                 DNA polymerase iota \[HGNC:9182\]                                       775        29         1,210      52           945        43         448       24         689     27    1,629   71    1,637   72    1,359   55
  POLK            2,895                79                 DNA polymerase kappa \[HGNC:9183\]                                      1,248      30         2,048      49           1,799      43         986       27         1,154   26    2,713   69    2,722   70    2,225   54
  PRMT1           2,886                80                 Protein arginine methyltransferase 1 \[HGNC:5187\]                      1,114      28         1,704      59           1,073      23         --        --         --      --    2,394   74    2,415   74    2,081   68
  RAD52           14,593               132                RAD52 homolog, DNA repair protein \[HGNC:9824\]                         --         --         2,291      25           --         --         --        --         --      --    3,043   40    3,496   54    3,121   49
  SIRT5           14,103               141                Sirtuin 5 \[HGNC:14933\]                                                --         --         2,086      30           --         --         --        --         --      --    2,769   40    3,211   44    2,844   42
  SLC6A3          1,006                94                 Solute carrier family 6 member 3 \[HGNC:11049\]                         461        49         773        71           584        72         252       54         453     49    976     91    973     90    823     73
  SMN2            1,633                53                 Survival of motor neuron 2, centromeric \[HGNC:11118\]                  --         --         1,136      44           1,059      28         --        --         --      --    1,520   49    1,521   49    1,209   45
  STK33           3,358                423                Serine/threonine kinase 33 \[HGNC:14568\]                               1,127      101        2,077      304          1,458      163        776       131        1,034   102   2,660   329   2,663   360   2,268   328
  TARDBP          1,802                60                 TAR DNA binding protein \[HGNC:11571\]                                  --         --         1,044      50           748        25         --        --         --      --    1,409   58    1,418   59    1,156   52
  TNFRSF10B       2,429                80                 TNF receptor superfamily member 10b \[HGNC:11905\]                      --         --         1,510      66           1,056      26         --        --         786     27    2,008   73    2,021   75    1,718   58
  TP53            2,310                198                Tumor protein p53 \[HGNC:11998\]                                        974        97         1,554      137          1,380      130        737       84         891     98    2,172   179   2,174   181   1,714   137
  TSHR            2,259                70                 Thyroid stimulating hormone receptor \[HGNC:12373\]                     968        25         1,579      58           1,317      43         727       35         --      --    2,133   68    2,131   67    1,739   64
  TUBB            697                  51                 Tubulin beta class I \[HGNC:20778\]                                     --         --         503        32           373        32         --        --         --      --    692     48    693     49    563     32
  USP1            2,356                64                 Ubiquitin specific peptidase 1 \[HGNC:12607\]                           877        30         1,425      46           1,260      45         697       29         833     30    1,972   55    1,985   58    1,557   44
  VDR             2,696                140                Vitamin D receptor \[HGNC:12679\]                                       1,161      44         1,901      101          1,673      80         915       50         1,076   43    2,530   127   2,536   128   2,059   107
  YES1            138                  101                YES proto-oncogene 1, Src family tyrosine kinase \[HGNC:12841\]         106        89         99         86           117        89         77        76         106     89    132     97    131     99    90      67

Subsequently, for each cell line GES dataset, we created a target---cell line GES dataset, restricting to compounds for which target activity was known as shown in [Figure 1](#F1){ref-type="fig"} (this step caused the number of possible models to drop from 1,104 to 990). Datasets for each target prediction task were split into a training set (67% of the data) and a test set (remaining 33% of the data). Two models for target activity prediction were trained using each subset: a first model used the 978-landmark GES as input (referred as GES models), and the second one used the Morgan fingerprints of corresponding compounds to fairly compare model performances (referred as Morgan FP models). Models were trained using random forest classifiers (Breiman, [@B5]).

The training was performed using a 4-fold cross-validation on training set to tune the maximum depth of tree, before assessing prediction performances on the test set. The number of trees per model was set to 200. Models were built in Python 2.7 using the sklearn package: to account for unbalanced dataset, the "class_weight" parameter was set to "balanced_subsample," to increase the weight of the under-represented class samples when training the trees (Pedregosa et al., [@B29]). A first step of feature selection was performed using an initial random forest classifier, computing the feature importance (Breiman, [@B5]). Sum of importance of all feature was 1, with each feature importance between 0 (non-important) and 1 (important). This step was performed 5 times, feature importance was averaged by feature, and only the 20 most important features were selected to be loaded into a final random forest model. This whole modeling pipeline, from train-test split to final model was performed 10 times per task, to account for variable performances depending on the dataset split.

Models were evaluated by counting the numbers of true positive (TP), true negative (TN), false positive (FP) and false negative (FN). These parameters were combined in the following metrics in order to compare model performances:
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Balanced accuracy allows for a fair evaluation of model performances when using unbalanced datasets, by averaging accuracy for each class (here active and inactives).

Quadrant Plots
--------------

Between each possible pair of compounds active on the same target and in each cell line, Dice distance between Morgan fingerprints, and cosine distance between GESs in given cell line were computed. These 2 distances were plotted in a 2D plot (referred as distance plot), Dice distance on X-axis and cosine distance on Y-axis. These plots were theoretically split in 4 quadrants.

Quadrant I in the top-right corner contains active compound pairs having different structures (Morgan fingerprints Dice distance \>0.5) and presenting different GESs (cosine distance \>0.5); quadrant II in top-left corner contains active compound pairs having similar structures (Morgan fingerprints Dice distance \<0.5) and presenting different GESs (cosine distance \>0.5); quadrant III in bottom-left corner contains active compound pairs having similar structures (Morgan fingerprints Dice distance \<0.5) and presenting similar GESs (cosine distance \<0.5); quadrant IV in bottom-right corner contains active compound pairs having different structures (Morgan fingerprints Dice distance \>0.5) and presenting similar GESs (cosine distance \<0.5). Number of active compound pairs in each quadrant were counted for each distance plot. Similar calculations were made using not only active compounds, but all compounds having an annotation (active or inactive) for considered target and profiled in the same cell line.

Results {#s3}
=======

In the present work, we investigated the link between compound structure information (*n* = 9,035) and their corresponding induced biological responses captured by GESs (*n* = 39,544) in human tumor cell lines and evaluated the potential of machine learning approaches to infer about molecular targets involved in the compound bioactivity. In addition, we compared these machine learning models using GESs with counterpart models using Morgan fingerprints.

Exploration of Chemical and Biological Spaces
---------------------------------------------

As a first step, to observe the diversity of the 9,035 compounds profiled in the 10 μM/24 h L1000 signature dataset, the corresponding chemical space was visualized. [Figure 2A](#F2){ref-type="fig"} is a 2-dimensional t-SNE representation of the chemical space, illustrating the variability in terms of Morgan fingerprints. The 9,035 compounds form a broad chemical space, with a mean Dice distance between compound pairs of 0.81 (ChEMBL has a mean pairwise Dice distance of 0.82). The center of the chemical space is mostly composed by small molecules having on average a molecular weight lower than 500 Da whereas the outer part is populated by clusters of compounds with higher molecular weights (\>500 Da). Overall, we were able to retrieve, in the public domain, at least one activity information for 7,837 compounds, from which 4,872 were active in at least one target. The majority of those compounds were found active in a low number of targets, on average 6 per compound, with a median of 2. Not surprisingly, a set of 23 kinase inhibitors were found to be active in more than 100 targets.

![Exploration of the 2D chemical space, along with the corresponding 2D biological space formed by all GES. **(A)** t-SNE on Morgan fingerprints from the 9,035 compounds in working dataset, representing the chemical space. Points corresponding to compounds for which there is no known target are represented by gray points (*n* = 4,163). Points corresponding to compounds for which there is at least one known target are in blue (*n* = 4,872), with darker blue depending on the increasing number of targets. **(B)** t-SNE on all GESs in the working dataset, representing the biological (transcriptomic response) space. Points corresponding to GESs are colored by cell line. **(C)** Biological space highlighting only PC3 and VCAP signatures, 2 cell lines originating from prostate cancer. **(D)** Biological space highlighting only A549 and HCC515 signatures, 2 cell lines originating from lung cancer.](fchem-08-00296-g0002){#F2}

[Figure 2B](#F2){ref-type="fig"} shows a t-SNE plot created using all GESs induced by the 9,035 compounds in the different cell lines to examine the complete biological space. This t-SNE is color coded by the different cell lines used to generate the gene signatures. Each cell line is represented by a set of 4 to 5 main clusters of GESs differing in size and some overlap of the cluster indicates similar GESs derived from different cell lines. In order to better appreciated the differences and communalities in GESs obtained with the selected compounds, t-SNE plots were created highlighting the clusters derived for cell lines originating from the same tumor type namely prostate tumor (VCAP and PC3 in [Figure 2C](#F2){ref-type="fig"}) and lung tumor (A549 and HCC515 in [Figure 2D](#F2){ref-type="fig"}). GESs derived from cell lines coming from the same tissue present very little overlap as can be observed in [Figures 2C,D](#F2){ref-type="fig"}.

These results illustrate the variability in the cellular modifications occurring during carcinogenesis (Hanahan and Weinberg, [@B14]) and show that each cell line represent a distinct biological space even if the cell lines are derived from the same tissue type. Interestingly, when comparing, for a set of compounds showing GESs in a single cluster in VCAP, GESs of these compounds in PC3 are spread across various clusters from the PC3 biological space (data not shown). This shows that each cell line explores different biological responses to compounds.

After having described the global variability of GESs in the different cell lines, we explored the chemical and biological spaces corresponding to active and inactive compounds on different targets. Since each compound-induced GES obtained in each cell line was shown to represent a unique biological space, t-SNE plots were computed per cell line in order to further explore the link between the different biological spaces and the corresponding chemical ones. For this, we decided to focus on three cell lines derived from different tissues and among the largest GES dataset generated that is to say A549 (lung cancer), MCF7 (breast cancer) and PC3 (prostate cancer). In addition, we selected 3 representative molecular targets showing different chemical and biological space profiles: compounds active on the glucocorticoid receptor (NR3C1) have similar structures, and similar GESs in some cell lines ([Figures 3A--D](#F3){ref-type="fig"}); tubulin beta I (TUBB) actives have more diverse structures but show similar GESs in each cell line considered in this work ([Figures 4A--D](#F4){ref-type="fig"}); and dopamine receptor D1 (DRD1) actives have diverse structure and GESs in every used cell line ([Figures 5A--D](#F5){ref-type="fig"}).

![NR3C1 active and inactives compounds in the chemical space and the different biological spaces formed by GES produced in a single cell line. **(A)** Chemical space; **(B)** t-SNE on all A549 signatures (A549 biological space); **(C)** t-SNE on all MCF7 signatures (MCF7 biological space); **(D)** t-SNE on all PC3 signatures (PC3 biological space). Points corresponding to NR3C1 actives are red (*n* = 54), NR3C1 inactives (*n* = 925) are blue, gray points have no available label concerning NR3C1 activity. Orange circles point out clustering of active compounds.](fchem-08-00296-g0003){#F3}

![TUBB active and inactives compounds in the chemical space and the different biological spaces formed by GES produced in a single cell line. **(A)** Chemical space; **(B)** A549 biological space; **(C)** MCF7 biological space; **(D)** PC3 biological space. Points corresponding to TUBB actives (*n* = 51) are red, TUBB inactives (*n* = 697) are blue, gray points have no available label concerning TUBB activity. Orange circles point out clustering of active compounds.](fchem-08-00296-g0004){#F4}

![DRD1 active and inactives compounds in the chemical space and the different biological spaces formed by GES produced in a single cell line. **(A)** Chemical space; **(B)** A549 biological space; **(C)** MCF7 biological space; **(D)** PC3 biological space. Points corresponding to DRD1 actives (*n* = 99) are red, DRD1 inactives (*n* = 1843) are blue, gray points have no available label concerning DRD1 activity.](fchem-08-00296-g0005){#F5}

NR3C1 actives compounds are mostly grouped together in the chemical space, as shown in [Figure 3A](#F3){ref-type="fig"} (*n* = 54; mean Dice distance = 0.67). Most of NR3C1 active GESs are also grouped in a cluster in the A549 biological space (*n* = 38; mean cosine distance = 0.76), visible in [Figure 3B](#F3){ref-type="fig"}, and remaining NR3C1 active GESs are spread across this biological space. Following the similarity principle, we could conjecture that other GESs that are close to this cluster are responses from other NR3C1 actives, especially in the PC3 biological space where the cluster contains compounds known to be active. The same phenomenon can be observed in the biological space of PC3 ([Figure 3D](#F3){ref-type="fig"}), HCC515, HA1E and VCAP (data not shown). Surprisingly, the GES clusters populated by numerous known NR3C1 actives in the biological spaces of A549 and PC3 also contain some known inactive compounds. In the biological spaces of MCF7, A375 and HT29, there is no such clustering, like shown in [Figure 3C](#F3){ref-type="fig"} representing the MCF7 biological space (*n* = 54; mean cosine distance = 0.92). Overall, these results show that compounds that are known to be active on the NR3C1 target can show a similar response in only certain cellular contexts.

TUBB actives compounds are spread in the chemical space (represented in [Figure 4A](#F4){ref-type="fig"}), indicating that they have diverse chemical structures (*n* = 51; mean Dice distance = 0.76). Most importantly, in each cell lines used in this work, GESs induced by TUBB actives compounds were similar (as illustrated in [Figures 4B--D](#F4){ref-type="fig"}), with a rather low mean cosine distance between active compounds ranging between 0.61 and 0.75 depending on the cell line dataset. Moreover, GESs of TUBB actives tend to be similar across all cell lines used in this work (highlighted in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). This conserved pattern in GESs induced by tubulin binding compounds likely illustrate certainly the ubiquitous role of tubulin polymerization of the eukaryotic cytoskeleton (Chaaban and Brouhard, [@B6]).

Finally, DRD1 actives compounds, that are represented in the chemical space t-SNE, have diverse chemical structures (*n* = 99; mean Dice distance = 0.81), associated with diverse GESs for the 3 cell lines presented (mean cosine distance between 0.88 and 0.92 depending on the cell line), as illustrated in [Figures 5A--D](#F5){ref-type="fig"}. Since GESs of active compounds in any cell lines are not similar, nor their chemical structures, actives cannot be easily discriminated from inactives using these two types of descriptors, as opposed to what was observed with NR3C1 actives that have similar structures, or TUBB actives having similar GESs in every cell line used in this study.

Model Performances: GES Vs. Morgan Fingerprints
-----------------------------------------------

Based on the observed GES similarity of compounds sharing target activity in appropriate cellular contexts, we tested building predictive machine learning models using GESs as descriptors and compare their performances with the ones of the models using Morgan fingerprints.

In order to avoid building models with too unbalanced datasets and to ensure a minimum of active compounds when testing model performances, we first pre-selected targets having at least 50 active compounds in the total dataset (representing between 1 and 63% of active compounds per target). We obtained one dataset per cell line---target combination (restricted to compounds having signatures in the considered cell line, as shown in [Figure 1](#F1){ref-type="fig"}) and carried out a second selection by performing prediction tasks using datasets containing at least 20 active compounds for the considered target (representing between 1 and 69% of active compounds per dataset). For each selected cell line---target dataset, one model using GESs (referred as GES model) was computed. In order to perform a fair comparison per task, one counterpart model using corresponding compound Morgan fingerprints (referred as Morgan FP model) was built using the same set of compounds as the one used in the corresponding GES models. Performances of models were evaluated using the balanced accuracy (BA) metric on a test set, to account for class imbalance in datasets. In total, 990 models were built for a total of 69 different targets. BAs of all built models are presented in [Table 3](#T3){ref-type="table"}. MCC of all built models are presented in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}.

###### 

Mean BAs of models (mean per condition).

                                                                                     **Cell line**   **A375**   **A549**   **HA1E**   **HCC515**   **HT29**   **MCF7**   **PC3**   **VCAP**                                                    
  ------------------------- -------------------------------------------------------- --------------- ---------- ---------- ---------- ------------ ---------- ---------- --------- ---------- ------ ------ ------ ------ ------ ------ ------ ------
  Enzyme                    15-Hydroxyprostaglandin dehydrogenase                    HPGD            0.5        0.65       0.51       0.7          0.52       0.67       0.5       0.72       0.51   0.68   0.5    0.71   0.52   0.67   0.52   0.64
                            Arachidonate 15-lipoxygenase                             ALOX15          0.54       0.74       0.57       0.75         0.54       0.67       0.5       0.63       0.5    0.73   0.56   0.74   0.65   0.75   0.53   0.75
                            ATP binding cassette B1                                  ABCB1           0.54       0.62       0.51       0.61         0.5        0.54       0.5       0.5        0.51   0.5    0.56   0.62   0.59   0.63   0.51   0.63
                            BRCA1, dna repair associated                             BRCA1           0.74       0.69       0.69       0.62         0.67       0.57       0.6       0.52       0.71   0.6    0.78   0.64   0.75   0.64   0.67   0.65
                            Cytochrome P450 1A2                                      CYP1A2          0.54       0.6        0.56       0.6          0.57       0.61       0.59      0.58       0.5    0.59   0.59   0.63   0.6    0.63   0.56   0.61
                            Cytochrome P450 2C19                                     CYP2C19         0.52       0.57       0.55       0.59         0.5        0.55       0.52      0.55       0.51   0.57   0.56   0.58   0.56   0.59   0.53   0.58
                            Cytochrome P450 2C9                                      CYP2C9          0.55       0.57       0.52       0.61         0.52       0.6        0.51      0.6        0.53   0.58   0.55   0.58   0.6    0.58   0.54   0.6
                            Cytochrome P450 3A4                                      CYP3A4          0.51       0.55       0.52       0.59         0.52       0.58       0.49      0.6        0.51   0.54   0.52   0.6    0.54   0.6    0.53   0.57
                            DNA polymerase beta                                      POLB            0.5        0.66       0.5        0.69         0.51       0.82       --        --         0.5    0.69   0.5    0.69   0.53   0.73   0.5    0.69
                            DNA polymerase eta                                       POLH            0.55       0.71       0.51       0.74         0.66       0.82       --        --         0.5    0.76   0.51   0.73   0.55   0.72   0.52   0.69
                            DNA polymerase iota                                      POLI            0.5        0.7        0.5        0.71         0.54       0.71       0.5       0.6        0.51   0.65   0.51   0.72   0.51   0.73   0.5    0.68
                            DNA polymerase kappa                                     POLK            0.58       0.77       0.51       0.78         0.56       0.83       0.52      0.79       0.5    0.76   0.54   0.81   0.56   0.83   0.5    0.83
                            Flap structure-specific endonuclease 1                   FEN1            0.5        0.72       0.5        0.68         0.5        0.77       --        --         0.5    0.74   0.5    0.77   0.51   0.75   0.5    0.7
                            Glutaminase                                              GLS             0.5        0.64       0.51       0.64         0.53       0.58       --        --         --     --     0.51   0.74   0.51   0.69   0.51   0.7
                            Growth factor, augmenter of liver regeneration           GFER            0.51       0.72       0.5        0.72         0.59       0.74       0.5       0.71       0.5    0.72   0.52   0.72   0.56   0.71   0.5    0.7
                            Hydroxysteroid 17-beta dehydrogenase 10                  HSD17B10        0.51       0.57       0.54       0.62         0.55       0.63       0.51      0.63       0.49   0.58   0.54   0.65   0.53   0.64   0.5    0.62
                            Janus kinase 2                                           JAK2            0.71       0.57       0.73       0.63         0.69       0.56       0.63      0.56       0.68   0.56   0.8    0.63   0.73   0.59   0.65   0.58
                            MDM2 proto-oncogene                                      MDM2            0.77       0.69       0.71       0.61         0.7        0.62       0.76      0.53       0.67   0.59   0.83   0.65   0.81   0.64   0.76   0.66
                            Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha   PIP4K2A         0.51       0.69       0.54       0.75         0.53       0.66       --        --         0.5    0.58   0.53   0.76   0.5    0.76   0.52   0.74
                            Phospholipase A2 group VII                               PLA2G7          0.5        0.71       0.51       0.65         0.57       0.72       --        --         0.5    0.69   0.54   0.69   0.57   0.71   0.51   0.69
                            Polo like kinase 1                                       PLK1            0.5        0.62       0.52       0.64         0.54       0.52       0.49      0.56       0.5    0.52   0.52   0.68   0.52   0.67   0.49   0.68
                            Serine/threonine kinase 33                               STK33           0.78       0.58       0.68       0.62         0.78       0.59       0.74      0.6        0.7    0.56   0.72   0.61   0.71   0.64   0.66   0.65
                            Ubiquitin specific peptidase 1                           USP1            0.5        0.54       0.51       0.58         0.51       0.53       0.51      0.53       0.5    0.55   0.52   0.57   0.57   0.59   0.5    0.57
                            YES proto-oncogene 1, Src family tyrosine kinase         YES1            0.7        0.72       0.67       0.7          0.71       0.72       0.63      0.69       0.66   0.71   0.66   0.75   0.7    0.72   0.54   0.68
  Epigenetic regulator      Bromodomain adjacent to zinc finger domain 2B            BAZ2B           0.6        0.66       0.54       0.68         0.63       0.69       0.52      0.6        0.5    0.65   0.55   0.67   0.6    0.66   0.53   0.68
                            Chromobox 1                                              CBX1            0.56       0.57       0.55       0.62         0.6        0.6        0.57      0.61       0.54   0.55   0.61   0.6    0.57   0.62   0.55   0.61
                            Lysine demethylase 4A                                    KDM4A           0.64       0.62       0.56       0.67         0.65       0.7        0.57      0.63       0.6    0.65   0.58   0.68   0.6    0.65   0.53   0.63
                            Lysine demethylase 4E                                    KDM4E           0.59       0.76       0.52       0.75         0.61       0.75       0.53      0.75       0.5    0.72   0.53   0.73   0.57   0.74   0.52   0.72
                            M-phase phosphoprotein 8                                 MPHOSPH8        0.52       0.53       0.52       0.64         0.54       0.64       0.51      0.65       0.5    0.54   0.63   0.63   0.54   0.64   0.51   0.65
                            Protein arginine methyltransferase 1                     PRMT1           0.5        0.65       0.51       0.71         0.5        0.54       --        --         --     --     0.52   0.7    0.51   0.71   0.51   0.72
                            Sirtuin 5                                                SIRT5           --         --         0.51       0.65         --         --         --        --         --     --     0.51   0.62   0.5    0.61   0.5    0.6
                            Survival of motor neuron 2, centromeric                  SMN2            --         --         0.5        0.62         0.51       0.56       --        --         --     --     0.52   0.63   0.52   0.6    0.5    0.62
  Ion channel               Potassium voltage-gated channel H2                       KCNH2           0.72       0.82       0.64       0.8          0.66       0.79       0.65      0.76       0.74   0.8    0.65   0.84   0.65   0.8    0.67   0.8
  Membrane receptor         5-hydroxytryptamine receptor 1A                          HTR1A           0.5        0.72       0.51       0.75         0.54       0.75       0.53      0.75       0.51   0.7    0.55   0.77   0.52   0.76   0.55   0.79
                            Cholinergic receptor muscarinic 1                        CHRM1           0.6        0.69       0.64       0.69         0.66       0.71       0.7       0.69       0.67   0.62   0.59   0.71   0.6    0.73   0.65   0.72
                            Cholinergic receptor muscarinic 4                        CHRM4           0.63       0.71       0.67       0.75         0.64       0.72       0.7       0.68       0.63   0.66   0.66   0.7    0.62   0.73   0.62   0.72
                            Cholinergic receptor muscarinic 5                        CHRM5           0.6        0.69       0.62       0.76         0.64       0.72       0.69      0.72       0.63   0.68   0.64   0.73   0.59   0.71   0.61   0.68
                            Dopamine receptor D1                                     DRD1            0.64       0.68       0.6        0.73         0.63       0.7        0.58      0.72       0.62   0.69   0.62   0.74   0.61   0.72   0.59   0.74
                            Dopamine receptor D2                                     DRD2            0.61       0.74       0.61       0.79         0.61       0.79       0.6       0.79       0.61   0.73   0.65   0.79   0.62   0.79   0.63   0.8
                            Dopamine receptor D3                                     DRD3            0.6        0.66       0.58       0.72         0.56       0.71       0.58      0.71       0.58   0.66   0.63   0.72   0.57   0.72   0.58   0.73
                            Neuropeptide S receptor 1                                NPSR1           --         --         0.59       0.64         0.5        0.55       --        --         --     --     0.63   0.66   0.57   0.66   0.58   0.63
                            Opioid receptor kappa 1                                  OPRK1           0.5        0.61       0.52       0.65         0.5        0.61       --        --         0.54   0.63   0.57   0.65   0.53   0.64   0.55   0.68
                            Thyroid stimulating hormone receptor                     TSHR            0.51       0.64       0.5        0.56         0.56       0.52       0.57      0.5        --     --     0.56   0.61   0.56   0.6    0.55   0.61
                            TNF receptor superfamily member 10b                      TNFRSF10B       --         --         0.69       0.61         0.56       0.52       --        --         0.7    0.56   0.71   0.61   0.78   0.58   0.65   0.56
  Other cytosolic protein   Heat shock protein 90 alpha A1                           HSP90AA1        0.53       0.65       0.5        0.67         0.59       0.73       --        --         0.53   0.67   0.55   0.67   0.59   0.65   0.51   0.64
                            Heat shock protein family B1                             HSPB1           0.58       0.58       0.54       0.53         0.63       0.58       0.54      0.51       0.5    0.55   0.66   0.59   0.66   0.61   0.55   0.57
  Secreted protein          Interleukin 1 beta                                       IL1B            0.62       0.55       0.65       0.6          0.65       0.55       0.65      0.55       0.66   0.57   0.68   0.63   0.69   0.62   0.63   0.62
  Structural protein        Tubulin beta class I                                     TUBB            --         --         0.81       0.8          0.82       0.78       --        --         --     --     0.88   0.82   0.84   0.8    0.82   0.8
  Transcription factor      Androgen receptor                                        AR              0.51       0.63       0.58       0.75         0.55       0.71       0.53      0.75       0.51   0.62   0.61   0.77   0.55   0.74   0.67   0.76
                            Jun proto-oncogene, AP-1 transcription factor subunit    JUN             0.6        0.69       0.54       0.63         0.58       0.65       0.56      0.61       0.59   0.67   0.6    0.65   0.57   0.67   0.6    0.63
                            Melanogenesis associated transcription factor            MITF            0.81       0.64       0.7        0.61         0.73       0.57       0.73      0.56       0.68   0.57   0.82   0.65   0.79   0.68   0.69   0.61
                            Nuclear factor kappa B1                                  NFKB1           0.51       0.51       0.5        0.66         0.51       0.5        0.5       0.51       0.55   0.5    0.5    0.63   0.51   0.64   0.51   0.63
                            Nuclear receptor 3C1                                     NR3C1           --         --         0.77       0.96         0.67       0.94       0.76      0.98       --     --     0.6    0.93   0.73   0.95   0.69   0.95
                            Nuclear receptor 5A1                                     NR5A1           0.55       0.53       0.65       0.56         0.64       0.57       --        --         --     --     0.72   0.62   0.73   0.62   0.65   0.6
                            Tumor protein p53                                        TP53            0.72       0.57       0.62       0.55         0.65       0.55       0.7       0.57       0.62   0.58   0.71   0.58   0.7    0.57   0.6    0.56
                            Vitamin D receptor                                       VDR             0.5        0.57       0.5        0.6          0.52       0.6        0.51      0.54       0.53   0.53   0.58   0.62   0.55   0.59   0.53   0.59
  Transporter               Abhydrolase domain containing 5                          ABHD5           0.51       0.57       0.51       0.66         --         --         --        --         --     --     0.55   0.68   0.54   0.68   0.53   0.69
                            Solute carrier family 6 member 3                         SLC6A3          0.64       0.65       0.62       0.66         0.65       0.65       0.67      0.62       0.61   0.65   0.66   0.66   0.66   0.67   0.64   0.68
  Unclassified protein      Ataxin 2                                                 ATXN2           0.78       0.5        0.7        0.62         0.74       0.52       0.7       0.53       0.69   0.58   0.72   0.62   0.72   0.61   0.7    0.61
                            ATPase family, AAA domain containing 5                   ATAD5           0.58       0.56       0.52       0.67         0.59       0.62       0.55      0.62       0.52   0.6    0.6    0.65   0.64   0.65   0.52   0.68
                            Endothelial PAS domain protein 1                         EPAS1           --         --         0.63       0.62         --         --         --        --         --     --     0.73   0.68   0.76   0.65   0.69   0.67
                            Geminin, DNA replication inhibitor                       GMNN            0.7        0.59       0.71       0.58         0.69       0.55       0.65      0.59       0.67   0.55   0.76   0.62   0.75   0.59   0.68   0.6
                            MLLT3, super elongation complex subunit                  MLLT3           --         --         0.5        0.54         --         --         --        --         --     --     0.55   0.55   0.51   0.63   0.51   0.67
                            MYC proto-oncogene, bHLH transcription factor            MYC             --         --         0.73       0.65         --         --         --        --         --     --     0.69   0.65   0.63   0.66   0.77   0.64
                            Nuclear factor, erythroid 2 like 2                       NFE2L2          0.57       0.51       0.57       0.6          0.55       0.58       0.57      0.59       0.58   0.53   0.56   0.61   0.61   0.6    0.59   0.6
                            Nucleotide binding oligomerization domain containing 1   NOD1            --         --         0.58       0.66         --         --         --        --         0.6    0.58   0.66   0.69   0.65   0.68   0.56   0.7
                            Nucleotide binding oligomerization domain containing 2   NOD2            0.5        0.53       0.53       0.61         0.56       0.54       --        --         0.52   0.53   0.58   0.68   0.61   0.68   0.56   0.64
                            RAD52 homolog, DNA repair protein                        RAD52           --         --         0.54       0.57         --         --         --        --         --     --     0.52   0.61   0.53   0.63   0.53   0.69
                            TAR DNA binding protein                                  TARDBP          --         --         0.5        0.56         0.51       0.54       --        --         --     --     0.54   0.55   0.54   0.54   0.5    0.57

*Target in lines, and cell line and used descriptor in columns. GES, model using gene expression signature. Morgan FP, model using chemical fingerprints from counterpart GES model dataset. Cells containing "-" corresponds to models that were not computed in cause of a too low number of actives (\<20) in the dataset to perform appropriate classification. Model presenting BA between 0.7 and 0.8 are highlighted in orange whereas those with BA \>0.8 are highlighted in red*.

Overall, GES model performances appeared to be variable depending on the predicted target and on the cell line that was used to generate the GESs, with a BA ranging from 0.49 to 0.88. Counterpart models trained with Morgan fingerprints also had variable performances, with a BA ranging from 0.50 to 0.98. On average, Morgan FP models (mean BA = 0.65) yielded better performances for the target activity prediction than their counterpart GES models (mean BA = 0.58). On the 495 cell line---target combinations, BA of GES models was higher than BA of counterpart Morgan FP models for 124 combinations (25%).

On the 990 models, 208 models reached a BA higher than 0.7 (21%) for 40 targets (59 GES models for 18 targets; 138 Morgan FP models for 28 targets), and 33 models reached a BA higher than 0.8 (3%) for 10 targets (10 GES models for 4 targets; 21 Morgan FP models for 7 targets). For all 138 Morgan FP models reaching BA higher than 0.7, BA was superior to counterpart GES models, and for the 59 GES models reaching BA higher than 0.7, only 6 had counterpart Morgan FP model with higher BA.

For NR3C1 activity prediction, Morgan FP models yielded a BA between 0.93 and 0.98 depending on the cell line dataset. It is not surprising considering that that NR3C1 actives have similar structure as shown in [Figure 3A](#F3){ref-type="fig"}. On the GES models, a BA of 0.77 was reached using the A549 signature dataset, correlating to similar GESs that were observed in the A549 biological space ([Figure 3B](#F3){ref-type="fig"}), whereas a BA of 0.6 was obtained using the MCF7 signature dataset (no GES cluster in MCF7 biological space, shown in [Figure 3C](#F3){ref-type="fig"}). A549 and MCF7 signature model performances cannot be fairly compared because they were built using different sets of compounds. In fact, performances of different GES models cannot be compared across cell lines nor across targets, performances can only be compared to observed similarity between active compounds in either chemical and biological space plots for a given target.

For TUBB activity prediction, GES models yielded BA between 0.81 and 0.88 depending on the cell line dataset, which was among the 10 best GES models. Interestingly, their counterpart Morgan FP models were not significantly underperforming (BA ranging from 0.78 to 0.82). Even though the TUBB active structures are diverse, the models still managed to identify structural fragments that could produce such predictive performance.

For DRD1 activity prediction, Morgan FP models yielded BA between 0.68 and 0.74 depending on the cell line dataset, and were always better than their counterpart GES model, with a BA ranging from 0.58 to 0.64.

Overall, we conclude that it was possible to build GES models with acceptable performances, performing similarly or better than their counterpart Morgan FP models in 25% of the target prediction tasks. Moreover, we see an important advantage in the GES models: they are theoretically performing independently of the chemical space considered, allowing target identification of new compounds even if their corresponding structural diversity is not represented in the training set.

Rationalizing Model Performances Using Distance Plots
-----------------------------------------------------

To further describe and understand the reasons for the differences in performances between GES model and Morgan FP model, for every dataset used in each cell line---target combinations, Morgan fingerprints Dice distance was plotted against GES cosine distance between each pair of active compounds in the given dataset.

Generated distance plots were split in 4 quadrants separated by a 0.5 threshold for Dice distance (dotted vertical line) and a 0.5 threshold for cosine distance (dotted horizontal line). Data points in top right (Quadrant I) represent pairs of active compounds showing diverse structures and different GESs in the considered cell line and contains most of compound pairs (average of 95.1%). Data points in top left (Quadrant II) represent pairs of active compounds showing similar structures while showing diverse GESs in the considered cell line (average of 1.9%). Data points in bottom left (Quadrant III) represents pairs of active compounds showing similar structures and similar GESs in the considered cell line and contains least compound pairs (average of 0.5%). Data points in bottom right (Quadrant IV) represents pairs of active compounds showing similar GESs while having different structures (average of 2.5%). Intuitively, we think that sample similarity within the same class (here: actives) is a good indicator to know if a machine learning model will be able to properly predict samples from this class.

Overall, the mean percentage of compound pairs (active and inactives) were 99.3, 0.3, 0.01 and 0.4% for quadrants I, II, III and IV respectively. Based on this dataset, compounds active toward a molecular target have on average more similar structures and GESs than the totality of the compounds.

We expected to reach good Morgan FP model prediction for combinations having a high proportion of points in quadrants II and III (similar structures), and good GES model prediction for combinations having a high proportion of points in quadrants III and IV (similar GESs). We evaluated the use of distance plots on the three targets and three cell lines used in previous space plots ([Figures 3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}). Similar work was performed using not only active compounds, but all compounds having at least one annotation for each of the three previously described targets, shown in [Supplementary Figure 2](#SM1){ref-type="supplementary-material"}.

For NR3C1 distance plots, there are approximately 10% of compound pairs in quadrants II and III of the 3 plots ([Figures 6A--C](#F6){ref-type="fig"}), coherent with good Morgan FP model performances. However, depending on which cell line the GESs were generated from, there were different proportions of compound pairs in quadrants III and IV: there are 20% of pairs for A549, and only 1% of pairs in MCF7. This is in agreement with what was observed in model performances: performance of GES models using the A549 dataset (BA = 0.77) was much better than performances using MCF7 dataset (BA = 0.60). Surprisingly, prediction using GESs from the PC3 dataset showed good performances (BA = 0.73), even though the proportion of active compound pairs in quadrants III and IV was around 1% (similar to the proportion observed for the MCF7 dataset that showed worse performances). This suggests that the GES model built with PC3 was able to capture a subset of genes to discriminate active compounds from inactives, even with active compounds showing different GESs.

![Morgan fingerprints Dice distance vs. GES cosine distance (distance plots). Different panels show information for pairs of NR3C1 **(A--C)**, TUBB **(D--F)**, and DRD1 **(G--I)**; active compounds in A549 **(A,D,G)**, MCF7 **(B,E,H)**, and PC3 **(C,F,I)** cell lines.](fchem-08-00296-g0006){#F6}

For TUBB distance plots ([Figures 6D--F](#F6){ref-type="fig"}), between 7 and 10% of compound pairs was observed in quadrants II and III, matching the good Morgan FP model performances with the 3 cell line datasets (BA ranging from 0.80 to 0.82). Most importantly, there are between 26 and 40% of compound pairs in quadrants III and IV, echoing the better performances of the GES models in these cell lines (BA ranging from 0.81 to 0.88).

For DRD1 distance plots ([Figures 6G--I](#F6){ref-type="fig"}), 98% of compound pairs are in quadrant I, leaving low number of active compound pairs in the other quadrants (with similar Morgan fingerprints and/or GESs). This is coherent with the average performances of GES (BA ranging from 0.68 to 0.74) and Morgan FP models (BA ranging from 0.58 to 0.64) built for this target.

Among the 50 best GES models, the mean percentage of active pairs in quadrants III and IV was 5.2% (vs. 2.3% in quadrants II and III). For the 50 best Morgan FP models, the mean percentage of active pairs in quadrants II and III was 4.0% (vs. 2.2% in quadrants III and IV). This suggests a positive relationship between sample similarity between active compounds using a given set of descriptors for active compounds and performances of models using these descriptors.

In the current work, GESs were shown to be effective descriptors to predict compound activity toward molecular targets. In 25% of target prediction tasks, GES models outperformed their counterpart Morgan FP models, especially when using GES produced in a cell line exhibiting similar GESs between compounds active toward the target of interest. Such GES models performs independently of the structural diversity of compounds that were used to produce GESs, offering a great opportunity to escape the classical chemical space limitations associated with QSAR models. In addition, t-SNE plots, along with 2D distance plots, can give insights to assess the predictive power of GESs and Morgan fingerprints for target prediction, based on a limited dataset depending on biological (GES and bioactivity assay) data availability.

Discussion {#s4}
==========

Our results show that compound-induced transcriptomic responses derived from cell lines have the potential to support target prediction of unknown compounds with large structural diversity. Interestingly, we observed that compound induced biological responses are mostly cell line specific even when cell lines are derived from the same tissue. Nevertheless, machine learning models using GESs were shown to perform well as long as the appropriate cell line was used. Exploring biological spaces can help to overcome the limitations derived from a restricted chemical space when using traditional QSAR. To improve the predictivity of GES models, we have identified several limitations, and discuss possible improvements.

Data Acquisition
----------------

First limitations come from gene expression data preprocessing. Gene expression values were obtained through multiple preprocessing steps from the initial generated raw data. For instance, there is a first peak deconvolution step to determine the gene expression levels, that as well as the plate-normalized z-scoring to obtain the normalized ("Level 5") can still be improved as already stated by Li et al. ([@B25]). Using GESs obtained with different preprocessing methods could potentially give more accurate normalized values leading to increased performances in machine learning models.

Secondly, the CMAP L1000 technology relies on the measurement of 978 landmark genes, representing about 5% of the human transcriptome (Pertea, [@B30]). The gene values of the remaining transcriptome can be inferred through different computational methods (Subramanian et al. ([@B36]) method reached good prediction for 81% of inferred genes), that are still under improvement (Blasco et al., [@B4]). We decided to only use the 978 landmarks as input data for the machine models generated, to reflect real measured gene expression. Doing so, we might have missed some valuable information captured by a change of expression of the non-measured genes. Therefore, it would be interesting to explore the potential added value of expanding the number of descriptors by adding the inferred gene information to the target prediction models.

Data Restrictions
-----------------

Another limitation is also coming with the activity dataset that was used. Since compound activity is a selective interaction, there is for each target a low number of active compounds compared to the number of inactive compounds. As a consequence, the training sets used for model building were highly unbalanced favorizing the prediction of the category inactive. Moreover, not every compound was tested for activity in all targets, leading to a sparse dataset (5% of total compound target interactions are known).

On top of this activity data limitation, not all available compounds were profiled in all the 8 cell lines used in this work. There were only about 600 compounds profiled in all the cell lines, which is too limited to build predictive models, with regard to available activity data. Consequently, one dataset per cell line was created, formed by compounds profiled in this cell line and resulting GESs. For each target prediction, the cell line datasets were restricted to compounds having a known label for the target of interest. Since each task used a different dataset, performances of models across cell lines or targets the comparison across GES models was not possible. The difference in dataset sizes is explaining at least partly the variation of performances of GES models across targets, ranging from models close to a random predictor (BA = 0.50) to good GES models (BA = 0.88), as well as the variation of performances of counterpart Morgan FP models (BA ranging from 0.50 to 0.98).

Biological Response Constraints
-------------------------------

Biologically, variation of GES model performances can also be caused by the difference in the pathway representation in the cell lines and consequently to compound induced signatures. Compounds active on a given target might show GESs with different degree of similarity or no similarity among the considered cell lines. as illustrated by the cases of NR3C1, TUBB and DRD1. Gene expression responses depend on the cellular context as shown in this work and elsewhere (Chen et al., [@B7]; Yu et al., [@B41]). Thus, the biological system in which the GESs are generated is of utmost importance for target prediction.

Due to practical aspects (scalability, low price, etc.), biological systems such as *in vitro* immortalized cell cultures (like cancer cell lines used in this work) are widely used, but they come with some disadvantages: they show limited physiological representativity and have been shown to drift along passages (Hughes et al., [@B17]). Even within the same cell line, it was shown that strains show different responses to the same compounds, indicating a reduced reproducibility between generated GESs (Ben-David et al., [@B3]). Ideally, the GESs should be derived from biological systems mimicking as much as possible the biological responses observed in the corresponding target organ.

The advantage of transcriptomic evaluations over single endpoint assays is that in theory they have the potential to capture integrative responses from compound treatments, ranging from on target activity at high potency to off-target activities at lower potencies, depending on the tested concentrations. GESs responses are also known to be variable depending on time exposition (Aguayo-Orozco et al., [@B1]). That is the reason why we selected data sets originating from the same study design. GESs measured at a concentration of 10 μM after 24 h of treatment of the cell lines were extracted, as this is the most represented experimental condition (De Wolf et al., [@B13]; Lv et al., [@B26]).

GES Models Versus Morgan FP Models
----------------------------------

We showed that using GES datasets produced by the Broad Institute with the CMAP L1000 technique (Subramanian et al., [@B36]), random forest models outperformed counterpart Morgan FP models for target prediction in 25% of the cases. Evidently, the outcome of this comparison is depending on the available data for the different targets to build the models as illustrated by the wide range of differences of BA between the two types of predictive models. Practically, both QSAR and transcriptomic descriptors represent good opportunities for target prediction, but each come with advantages and constraints that needs to be considered when building predictive models.

QSAR models for target prediction are widely used because of the wide dataset available, with existing databases like PubChem or ChEMBL. Most QSAR descriptors are discrete unambiguous values extracted from the chemical formula of compounds, thus easily computed. In the context of hit discovery, a major drawback of QSAR models is that they show significant error rate when trying to predict activity for compounds that are too structurally different from the training set (Cherkasov et al., [@B9]). Using a new set of descriptors, like compound bioactivity such as GESs extracted from *in vitro* experiments, can help in target prediction while escaping from the classical chemical space limitation observed in QSAR approaches.

On the other hand, GESs represents a number of changes on a certain number of genes (the 978 landmarks), capturing the effect of compounds. These data could be used to make inference about biology (i.e., finding targets or biomarkers). Each cell line shows a unique biological space that can be explored. However, these biological experiment data are prone to technical and biological variability like discussed earlier. Gene expression can be measured in different dose and time conditions, adding dimensions to explore in order to find the conditions reaching best performances in GES models. Finally, the gene expression measurements are more and more cost effective, making the use of such data at a large scale possible.

When exploring a new chemical class in hit discovery, evaluating chemical-induced biological responses in appropriate cell-lines using transcriptomic profiling can support chemical prioritization. This biologically-based approach present the advantage in a given biological space of being in principle chemical space independent as opposed to QSAR modeling that is constrained by the chemical space of the training set. Furthermore, during lead optimization, biological spaces inform about the direct activity of candidates, which can help fine-tuning their desired activity profile, by optimizing the on-target activity. It has been recently shown that this type of data can be used for *de novo* chemical design fulfilling a specific GES (Méndez-Lucio et al., [@B27]). In a chemical safety approach, it can be used to detect compound interaction with off-targets. However, a difference between these 2 applications would be the conditions in which the GESs are generated: on-target effects are observable at low concentrations (Kd often in the nanomolar range), while off-target effect are known to typically appear at higher concentration as illustrated by Li et al. ([@B24]).

In conclusion, in this work, we evaluated the use of a large public dataset of compound-induced transcriptomic data, to predict compound activity on 69 molecular targets. We compared machine learning models built with transcriptomics data with counterpart models built using Morgan fingerprints. Active compounds on a given target could exhibit similar signatures in one or multiple cell lines, independent from the chemical structure similarity between these active compounds. For 25% of the tasks, random forest models using transcriptomics signatures performed similarly or better than counterpart models built with Morgan fingerprints, occurring mostly using signatures produced in cell lines that showed similar signatures for active compounds on a given target. Compound-induced transcriptomic data could offer a great opportunity for target prediction based on cell response similarity and allows to circumvent the applicability domain limitation of QSAR models.
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